Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106

Showing 1-25 of 106 citing articles:

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Kanyin Liane Ong, Lauryn K Stafford, Susan A. McLaughlin, et al.
The Lancet (2023) Vol. 402, Iss. 10397, pp. 203-234
Open Access | Times Cited: 1781
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 705-719
Closed Access | Times Cited: 174
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 144
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 81
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 17
Probability of 5% or Greater Weight Loss or BMI Reduction to Healthy Weight Among Adults With Overweight or Obesity
Lyudmyla Kompaniyets, David S. Freedman, Brook Belay, et al.
JAMA Network Open (2023) Vol. 6, Iss. 8, pp. e2327358-e2327358
Open Access | Times Cited: 32
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
Differential mechanisms affecting weight loss and weight loss maintenance
Michael Rosenbaum, Gary D. Foster
Nature Metabolism (2023) Vol. 5, Iss. 8, pp. 1266-1274
Closed Access | Times Cited: 26
Self‐Assembled Oligopeptoplex‐Loaded Dissolving Microneedles for Adipocyte‐Targeted Anti‐Obesity Gene Therapy
Hee Kyoung Choi, Juhyeong Hong, Yuha Seo, et al.
Advanced Materials (2024) Vol. 36, Iss. 16
Closed Access | Times Cited: 14
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 12
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 12
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Guy Pelletier, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 617-617
Open Access | Times Cited: 11
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
Gustavo de Oliveira Almeida, Thiago Nienkötter, Caroline Cristine Almeida Balieiro, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 4, pp. 509-521
Closed Access | Times Cited: 9
NK2R control of energy expenditure and feeding to treat metabolic diseases
Frederike Sass, Tao Ma, Jeppe H. Ekberg, et al.
Nature (2024) Vol. 635, Iss. 8040, pp. 987-1000
Open Access | Times Cited: 9
Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
Beverly G. Tchang, Michael G. Knight, Kasper Adelborg, et al.
Obesity (2025)
Open Access | Times Cited: 1
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Robert F. Kushner, Donna H. Ryan, John Deanfield, et al.
Obesity (2025)
Open Access | Times Cited: 1
Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials
Sarah Kanbour, Rwedah A. Ageeb, Rayaz A. Malik, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
Ruiyi Zhu, Shuchun Chen
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 17
Obesity and Weight Loss Strategies for Patients With Heart Failure
Amanda R. Vest, Philip R. Schauer, Jo E. Rodgers, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 9, pp. 1509-1527
Closed Access | Times Cited: 6
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff, Timo D. Müller
Physiology (2024) Vol. 39, Iss. 3, pp. 142-156
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top